High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Area of Science:

• Oncology
• Biotechnology
• Drug Discovery

Background:

• Patient-derived tumor organoids (PDOs) accurately recapitulate human tumor architecture and function.
• Traditional PDO cultures are unsuitable for high-throughput screening (HTS) due to heterogeneity and large cluster formation.
• Current PDO assays are low-throughput, costly, and difficult to standardize.

Purpose of the Study:

• To develop a simpler, more accurate HTS for evaluating anticancer drugs and immunotherapies using PDOs.
• To establish an in vitro HTS system compatible with standard well-plate formats for PDO drug screening.
• To create an HTS for assessing immune response, specifically antibody-dependent cellular cytotoxicity (ADCC), using PDOs.

Main Methods:

• Established PDOs from solid tumors for culture in 384-well plates.
• Developed an in vitro HTS utilizing PDOs in 384-well plates for drug potency evaluation.
• Created an HTS for ADCC assessment using PDOs cultured in 96-well plates.

Main Results:

• Successfully developed an in vitro HTS using PDOs for evaluating anticancer drug potency.
• Established a novel HTS system for assessing ADCC activity, representing immune response.
• The new HTS systems offer improved throughput and accuracy for PDO-based drug evaluation.

Conclusions:

• The developed HTS systems overcome limitations of traditional PDO assays for drug screening.
• These novel PDO-based HTS platforms facilitate efficient evaluation of anticancer drugs and immunotherapies.
• This approach enhances preclinical cancer modeling and accelerates drug discovery and development.